Cubist buys Optimer for $524mm in cash, plus CVRs
Executive Summary
Acute care firm Cubist Pharmaceuticals Inc. is acquiring all the outstanding common stock of public antibiotics developer Optimer Pharmaceutical Inc. for $10.75 per share (a 24% discount) in cash, or a total of $523.7mm. The transaction also includes earn-outs in the form of contingent value rights (CVRs), which would give Optimer shareholders up to $5.00 for each share they own--a total of $243.6mm--if certain net sales of Dificid (fidaxomicin) are met.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice